PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY

被引：0
|
作者：
Kaplan, Jess
Bousvaros, Athos
Turner, Dan
Dubinsky, Marla C.
Komocsar, Wendy
Larkin, Amy E.
Johns, Jordan
Zhang, Xin
Little, Cheryl A.
Crandall, Wallace
Arora, Vipin
Hyams, Jeffrey S.
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
781
引用
收藏
页码：S169 / S169
页数：1
相关论文
共 50 条
  • [21] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023,
  • [22] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Laiyi Chua
    Stuart Friedrich
    Xin Cindy Zhang
    Clinical Pharmacokinetics, 2023, 62 (10) : 1479 - 1491
  • [23] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 213 QUASAR STUDY RESULTS THROUGH WEEK 12
    Allegretti, Jessica R.
    Rubin, David T.
    Bressler, Brian
    Huang, Kuan-Hsiang G.
    Shipitofsky, Nicole
    Germinaro, Matthew
    Zhang, Hongyan
    Johanns, Jewel
    Feagan, Brian
    Sandborn, William J.
    Sands, Bruce E.
    Hisamatsu, Tadakazu
    Lichi, Gary R.
    Lichtenstein, Gary R.
    Panes, Julian
    Dignass, Axel
    GASTROENTEROLOGY, 2022, 162 (07) : S963 - S964
  • [24] Extended Induction of Mirikizumab Sustains Efficacy and Safety Over 104 Weeks for Patients With Moderately to Severely Active Ulcerative Colitis Refractory to Initial Induction
    D'Haens, Geert
    Navabi, Seyedehsan
    Chan-Diehl, Faye
    Moses, Richard E.
    Walter, James
    Gibble, Theresa Hunter
    Laharie, David
    Gisbert, Javier P.
    Vermeire, Severine
    Kobayashi, Taku
    Regueiro, Miguel
    Johns, Jordan
    Charabaty, Aline
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S871 - S872
  • [25] THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
    Rubin, David T.
    Allegretti, Jessica R.
    Panes, Julian
    Shipitofsky, Nicole
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Dignass, Axel
    GASTROENTEROLOGY, 2024, 166 (05) : S180 - S180
  • [26] Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis
    Sturm, A.
    Sebastian, S.
    Faye, A. S.
    Armuzzi, A.
    Buisson, A.
    Halfvarson, J.
    Zeissig, S.
    Kochar, B.
    Maier, S.
    Redondo, I
    Moses, R. E.
    Keohane, A.
    Watanabe, K.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2005 - i2006
  • [27] HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Pai, Rish
    Canavan, James
    Tuttle, Jay
    Durante, Michael
    Arora, Vipin
    Milch, Catherine
    Harpaz, Noam
    D'Haens, Geert R.
    Sands, Bruce E.
    Sandborn, William J.
    GASTROENTEROLOGY, 2020, 158 (06) : S1187 - S1187
  • [28] The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
    Dignass, A.
    Rubin, D.
    Bressler, B.
    Huang, K. H.
    Shipitofsky, N.
    Germinaro, M.
    Zhang, H.
    Johanns, J.
    Feagan, B.
    Sandborn, W.
    Sands, B.
    Hisamatsu, T.
    Lichtenstein, G.
    Panes, J.
    Allegretti, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I025 - I026
  • [29] EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
    Peyrin-Biroulet, Laurent
    Loftus, Edward V.
    Danese, Silvio
    Vermeire, Severine
    Sandborn, William J.
    Fogel, Ronald P.
    Nijhawan, Sandeep
    Kempinski, Radoslaw
    Filip, Rafal
    Hospodarskyy, Ihor
    McNally, John
    Yun, Chohee
    Zhao, Sally
    Liu, Xiaopeng
    Tasset, Chantal T.
    Besuyen, Robin
    Watanabe, Mamoru
    Schreiber, Stefan
    Rogler, Gerhrad
    Hibi, Toshifumi
    Feagan, Brian G.
    GASTROENTEROLOGY, 2021, 160 (06) : S350 - S350
  • [30] Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
    Kobayashi, Taku
    Matsuoka, Katsuyoshi
    Watanabe, Mamoru
    Hisamatsu, Tadakazu
    Hirai, Fumihito
    Milata, Joe
    Li, Xingyuan
    Morris, Nathan
    Arora, Vipin
    Ishizuka, Tomoko
    Matsuo, Koji
    Satoi, Yoichi
    Milch, Catherine
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2024, 22 (02) : 172 - 185
12345